Afatinib

Recent Results Cancer Res. 2018:211:199-215. doi: 10.1007/978-3-319-91442-8_14.

Abstract

Afatinib (BIBW 2992, US: GilotrifTM, other countries: Giotrif©) is an irreversible blocker of the ErbB family, acting at the tyrosine kinases of these proteins. In 2013, it was approved by the FDA and the EMA for the treatment of adults with advanced, EGFR mutation-positive non-small-cell lung cancer. Further investigations for the treatment of many other tumors with afatinib, e.g., HNSCC and breast cancer, are ongoing.

Keywords: Afatinib; EGFR; Mutation; NSCLC; Solid tumors.

Publication types

  • Review

MeSH terms

  • Afatinib
  • Animals
  • Antineoplastic Agents / pharmacology*
  • Humans
  • Neoplasms / drug therapy*
  • Protein Kinase Inhibitors / pharmacology*
  • Quinazolines / pharmacology*
  • Radiation-Sensitizing Agents / pharmacology*

Substances

  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Quinazolines
  • Radiation-Sensitizing Agents
  • Afatinib